MOOK 肺癌の臨床 2007-2008

出版社: 篠原出版新社
著者:
発行日: 2007-03-30
分野: 臨床医学:一般  >  癌/腫瘍一般
ISBN: 9784884126162
電子書籍版: 2007-03-30 (第1版第1刷)
書籍・雑誌
≪全国送料無料でお届け≫
発送目安:8~14営業日

8,800 円(税込)

電子書籍
章別単位で購入
ブラウザ、アプリ閲覧

4,400 円(税込)

商品紹介

現在、そして今後の肺癌診療につながる集学的内容にそった編集方針のもと、この一冊で最新の肺癌治療を展望することが出来る内容をめざし、季刊『肺癌の臨床』からの編集委員が気鋭の執筆者を厳選して構成。肺癌治療に携わるすべての医療関係者に読んでいただきたい、価値ある一冊。

目次

  • 表紙
  • CONTENTS
  • AUTHOR
  • 疫学
  • 肺癌の年次動向と展望
  • 肺癌は遺伝するか ? : 日本のコホート研究からのエビデンス
  • 女性の肺癌
  • 病理・分子生物学
  • 肺腺癌研究の進歩
  • EGFR変異の高感度検出法
  • 肺癌遺伝子変異の特性
  • 肺神経内分泌性腫瘍の診断と組織発生
  • アスベスト曝露による肺癌
  • 発見・診断
  • 前がん病変の早期診断 ( 分子生物学的側面も加味して )
  • 肺野末梢の早期肺癌をどう定義するか
  • 日常診療 ( 他疾患経過観察中 ) における胸部検診
  • CT検診の妥当性と評価
  • PET検診は是か否か
  • 極細径気管支鏡
  • 気管支鏡下マイクロサンプリング法による気道上皮被覆液の解析 - 腫瘍マーカー解析とプロテオミクス -
  • 肺門・縦隔病変に対する超音波気管支鏡下生検法
  • 肺癌を合併しやすい呼吸器疾患
  • マススペクトロメトリーによる血清タンパク質解析
  • 治療 ( 小細胞肺癌 )
  • 小細胞肺癌の化学療法の現状と課題
  • 限局型小細胞肺癌の化学放射線療法の最近の動向
  • 進展型小細胞癌の臨床試験・治療戦略
  • 小細胞癌に対するDose Intensive Chemotherapy
  • 高齢者小細胞癌の治療
  • 再発小細胞肺癌の治療戦略
  • 治療 ( 非小細胞肺癌 )
  • 肺癌に対する胸腔鏡手術
  • I期肺癌に対する体幹部定位照射 - 重粒子線, 陽子線を含む -
  • EGFR - TKIの現状 : 基礎 - EGFRの感受性を決定する因子update
  • EGFR - TKIの現状 : 臨床
  • VEGFターゲットの治療
  • 肺線維症を合併する肺癌に対する治療方針
  • 非小細胞肺癌の新しい化学療法 - TS - 1, アリムタ -
  • 切除不能III期非小細胞癌の新しい治療法
  • 診断・治療 ( 中皮腫, 胸膜・縦隔腫瘍 )
  • 胸膜中皮腫の年次動向と展望
  • 中皮腫を早期発見するために何をすべきか
  • 胸膜中皮腫の免疫組織化学的染色による確定診断
  • 中皮腫の血液診断マーカー
  • 中皮腫の遺伝子異常 - マイクロアレイを用いた網羅的解析
  • 悪性胸膜中皮腫に対する外科手術成績からみた治療戦略
  • 悪性胸膜中皮腫に対する放射線治療の現状
  • 悪性胸膜中皮腫の治療 : 手術の適応と実践
  • 悪性胸膜中皮腫の治療 - 内科的治療の進歩 -
  • 胸腺腫・胸腺癌における内科的治療の動向
  • 胸膜・胸壁腫瘍の画像診断
  • 胸腺上皮性腫瘍の外科治療成績
  • 縦隔胚細胞腫瘍に対する化学療法
  • 奥付

おすすめ商品

この書籍の参考文献

参考文献のリンクは、リンク先の都合等により正しく表示されない場合がありますので、あらかじめご了承下さい。

本参考文献は電子書籍掲載内容を元にしております。

疫学

P.8 掲載の参考文献
P.12 掲載の参考文献
1) Ferlay JBF, Pisani P, Parkin DM : GLOBOCAN 2002 : Cancer Incidence, Mortality and Prevalence Worldwide IARC Cancer Base No. 5. version 2.0, IARCPress. p. Lyon, 2004 http://www-dep.iarc.fr/GLOBOCAN 2002 database.
3) IARC monographs on the evaluation of carcinogenic risks to humans : tobacoo smoke and involuntary smoking. LARC Monogr Eval Carcin og Risks Human Suppl 83 : 1-1452, 2004
4) Koop CE, Luoto J : "The Health Consequences of Smoking : Cancer," overview of a report of the Surgeon General. Public Health Rep 97 (4) : 318-324, 1982
6) Stanley KE : Lung cancer and tobacco-a global problem. Cancer Detect Prev 9 (1-2) : 83-89, 1986
20) Risch HA, et al : Are female smokers at higher risk for lung cancer than male smokers? A case-control analysis by histologic type. Am J Epidemiol 138 (5) : 281-293, 1993
32) Shields PG, et al : Dopamine D4 receptors and the risk of cigarette smoking in African-Americans and Caucasians. Cancer Epidemiol Biomarkers Prev 7 (6) : 453-458, 1998
36) Bromen K, et al : Aggregation of lung cancer in families : results from a population-based case-control study in Germany. Am 」 Epidemiol 1 52 (6) : 497-505, 2000
P.17 掲載の参考文献
4) Ryberg D, Hewer A, Phillips DH, et al : Different susceptibility to smoking-induced DNA damage among male and female lung cancer patients. Cancer Res 54 (22) : 5801-5803, 1994
5) Mollerup S, Ryberg D, Hewer A, et al : Sex differences in lung CYPIAI expression and DNA adduct levels among lung cancer patients. Cancer Res 59 (14) : 3317-3320, 1999
8) Stabile LP, Davis AL, Gubish CT, et al : Human non-small cell lung tumors and cells derived from normal lung express both estrogen receptor alpha and beta and show biological responses to estrogen. Cancer Res 62 (7) : 2141-2150, 2002
12) Lynch TJ, Bell DW, Sordella R, et al : Activating mutations in the epidermal groWth factor receptor underlying responsiveness of non-small-cell lung cancer to gefitinib. N Engl J Med 350 (21) : 2129-2139, Epub 2004 Apr 29, 2004

病理・分子生物学

P.25 掲載の参考文献
2) Suzuki A, Shimosato Y, Nishiaki Y, et al : X-ray features of small cell carcinoma and adenocarcinoma of the lung. Shindan to Chiryo 65 : 1424, 1977 (in Japanese)
5) Shimosato Y, Kodama T, Kameya T, et al : Morphogenesis of Lung cancer (Shimosato Y, Melamed, MR, Nettesheim P, eds), Boca Ratton, Florida. CRC Press : 65-89, 1982
9) Nakayama H, Noguchi M, Tsuchiya R, et al : Clonal growth of atypical adenomatous hyperplasia of the lung : cytofluorometric analysis of nuclear DNA content. Mod Pathol 3 : 314-320, 1990
10) Yokozaki M, Kodama T, Yokose T, et al : Differentiation of atypical adenomatous hyperplasia and adenocarcinoma of the lung by use of DNA ploidy and morphometric analysis. Mod Pathol 9 : 1156-1164, 1996
13) Mitsudomi T, Hamajima N, Ogawa M, et al : Prognostic significance of p53 alterations in patients with non-small cell lung cancer : a meta-analysis. Clin Cancer Res 6 : 4055-4063, 2000
14) Tsuchiya E, Furuta R, Wada N, et al : High K-ras mutation rates in goblet-cell-type adenocarcinomas of the lungs. J Cancer Res Clin Oncol 121 : 577-581, 1995
P.31 掲載の参考文献
4) Tokumo M, Toyooka S, Kiura K, et al : The relationship between epidermal growth factor receptor mutations and clinicopathologic features in non-small cell lung cancers. Clin Cancer Res 3 : 1167-1173, 2005
P.39 掲載の参考文献
4) Lynch TI, Bell DW, Sordella R, et al : Activating mutations in the epidermal growth factor receptor underlying responsiveness of non-small-cell lung cancer to gefitinib. NEJM 350 (21) : 2129-2139, 2004
P.46 掲載の参考文献
2) Travis WD, Brambilla E, Mueller-Hermelink HK, et al : (ed.) Pathology and genetics of tumours of the lung, pleura, thymus and heart. WHO classhication of tumours 7, LARC press, 2004
3) 日本肺癌学会. 『臨床・病理肺癌取扱い規約改訂第6版』, 金原出版, 2003
4) 石川雄一. 肺の神経内分泌腫瘍のスペクトラム-鑑別診断のために. 病理と臨床 21 : 507-511, 2003
10) Stuml N, Rossi G, Lantuejoul S, et al : Expression of thyroid transcription factor-1 in the spectrum of neuroendocrine cell lung proliferations with special interest in carcinoids. Hum Pathol 33 : 175-182, 2002
13) Bhattachaliee A, Richards WG, Staunton J, et al : Classification of human lung carcinomas by mRNA expression profiling reveals distinct adenocarcinoma subclasses. Proc Natl Acad Sci USA 98 (24) : 13790-13795, 2001
P.55 掲載の参考文献
1) IARC : Biological Effects of Asbestos. Bogovski P, Gilson JC, Timbell V, Wagner JC eds. LARC SCi Publica tions No. 8, WHO, Geneva, 1-346, 1973
3) 財団法人厚生統計協会 人口動態 厚生の指標 臨時増刊. 国民衛生の動向, 46-47, 2006
7) Morinaga K, Yokoyama K, Sakatani K, et al : (Hurych J. Lesage M, David A, eds.) Lung cancer mortality among the asbestosis by smoking habit. Proceeding of VIIIh international Conference on occupational lung disease. ILO, Geneva, 372-376, 1989
8) 森永謙二 : 石綿関連疾患の疫学. Mebio 23 : 12-20, 2006
9) Hessel PA, Gamble JF and McDonald JC : Asbestos, asbestosis and lung cancer : acritical assessment of the epidemiological evidence. Thorax 60 : 433-436, 2006
11) 神山宣彦 : (森永謙二編). 第2節 石綿小体. 改訂新版 職業性石綿曝露と石綿関連疾患 -基礎知識と労災補償-, 79-101, 2005
12) 岸槌健太郎 : ヒト肺内に沈着するアスベスト繊維の分析. -殊に肺癌, 悪性中皮腫発生との相関-. 広大医誌 43 : 279-296, 1995
13) 北川正信, 村井嘉寛 : 石綿関連疾患の病理. 病理と臨床 7 : 702-708, 1989
14) 立山義朗, 井内康輝, 米原修治ら : アスベスト曝露と肺癌の相関 -手術摘出肺を用いた病理学的検討-. 病理と臨床 11 : 967-973, 1993
16) 加藤勝也 : 増補改訂版 アスベスト関連疾患日常診療ガイド アスベスト関連疾患を見逃さないために 独立行政法人労働者健康福祉機構編. 労働調査会 27-31, 2006
17) 坂谷暁夫, 武島幸男, 井内康輝ら : アスベスト曝露が証明された肺癌の1例. 広島医学 59 : 247-248, 2006
18) 石田啓, 武島幸男, 井内康輝ら : アスベスト肺に肺癌を合併した1例. 広島医学 55 : 645-646, 2002
19) Consensus report : Anbestos, asbestosis, and cancer : the Helsinki criteria for diagnosis and attribution. Scand J Work Environ Health 23 : 311-316, 1997
23) Wang X, Chrustiani DC, Wiencke JK, et al : Mutations in the p53 gene in lung cancer are associated with cigarette smoking and asbestos exposure. Cancer Epiderol Biolomarker Prev 4 : 543-548, 1995
24) Nelson HM, Christiani DC, Wiencke JK et al : K-ras mutation and occupational asbestos exposire in lung adenocarcinoma : asbestos-related cancer without asbestosis. Cancer Res 54 : 4570-4573, 1999
25) Nelson HH, Wiencke JK, Gunn L, et al : Chromosome 3p14 alterations in lung cancer : evidence that FHIT exon deletion is a target of tobacco carcinogens and asbestos. Cancer Res 58 : 1804-1807, 1998

発見・診断

P.62 掲載の参考文献
2) Noguchi M, Shimosato Y : The development and progression of adenocarcinoma of the lung. In : Hasnen H, ed. Lung Cancer V, Kluwer Academic. Boston, pp 131-142, 1994
4) 森永正二郎, 下里幸雄 : 気管支, 肺の微小癌. D, 肺末梢微小腺癌の病理. 病理と臨床 5 (臨増) : 74-80, 1987
7) Nakayama H, Noguchi M, Tsuchiya R, et al : Clonal growth of atypical adenomatous hyperplasia of the lung : Cytofluorometric analysis of nuclear DNA content. Mod Pathol 3 : 314-320, 1990
9) 野口雅之 : 肺腺癌の上皮内腫瘍と多段階発癌. 呼吸 17 : 224-229, 1998
10) Aoyagi Y, Yokose T, Minami Y, et al : Accumulation of loss of heterozygosity and multistep carcinogenesis in pulmonary adenocarcinoma. Cancer Research 61 : 7950-7954, 2001
P.69 掲載の参考文献
P.77 掲載の参考文献
2) Stellman S, Takezaki T, Wang L, et al : Smoking and lung cancer risk in American and Japanese men : an international case-control study. Cancer Epidemiol Biomarkers Prev 10 : 1193-1199, 2001
10) 大塚義紀, 浮田英明, 正木芳孝・他 : 特発性間質性肺炎 (IIP) からの肺癌発症-prospective study-. 日胸疾会誌 29 : 560-565, 1991
11) 青山克彦, 星永進, 生方幹夫・他 : 特発性間質性肺炎の臨床-肺癌の合併とその対応. 日胸 62 : S114-S120, 2003
14) 低線量CTによる肺癌検診のあり方に関する合同委員会 : 低線量CTによる肺癌検診の手引き. 金原出版, 東京, 89, 2004
15) The Early Lung Cancer Action Project (ELCAP) : Survival of patients with stage I lung cancer detected on CT screening. N Engl J Med 355 : 1763-1771, 2006
P.82 掲載の参考文献
1) Melamed MR, Flehinger BJ, Zaman MB, et al : Screening for early lung cancer : results of the Memorial Sloan-Kettering study in New York Chest 86 : 44-53, 1984
4) Tsukada H, Kurita Y, Yokoyama A, et al : An evaluation of screening for lung cancer in Niigata Prefecture, Japan : A population-based case-control study. Br J Cancer 85 : 1236-1331, 2001
10) Nawa T, Nakagawa T, Kusano S, et al : Lung cancer screening using low-dose spiral CT-results of baseline and oneyear follow-up studies. Chest 122 : 15-20, 2002
12) The International Early Lung cancer Action Program Investigators Survival of Patients with Stage I Lung Cancer Detected on CT Screening, NEJM 355 : 1763-1771, 2006
13) 厚生労働省科学研究費補助金 第3次対がん総合戦略研究事業 : 革新的な診断技術を用いたこれからの肺がん検診手法の確立に関する研究 (CT肺がん検診有効性コホート研究・喀疾細胞診有効性症例対照研究), 主任研究者鈴木隆一郎, 平成17年度総括・分担研究報告書
14) 低線量CTによる肺癌検診のあり方に関する合同委員会 : 低線量CTによる肺癌検診の手引き, 金原出版, 東京, 2004
15) 平成17年度がん研究助成金「がん検診の適切な方法とその評価法の確立に関する研究」班 (主任研究者祖父江友孝) http://canscreen.ncc.go.jp/index.html
16) 花井耕造 : 胸部CTスクリーナー制度の構築について. CT検診 13 : 8, 2006
17) 長尾啓一 : 低線量CTによる肺癌検診の資格認定の必要性. 日本胸部臨床 65 : S114-118, 2006
19) www.iaslc.org.
P.88 掲載の参考文献
2) 窪田和雄 : FDG-PETの原理と評価法. 画像診断 23 : 1118-1128, 2003
3) Higashi K, Ueda Y, Seki H, et al : Fluorine-18-FDG PET imaging is negative in bronchioloalveolar lung carcinoma. J Nucl Med 39 (6) : 1016-1020, 1998
4) Stahl A, Ott K, Weber WA, et al : Correlation of FDG uptake in gastric carcinomas with endoscopic and histopathological fingings. J Nucl Med 42 : 78, 2001
5) Torizuka T, Tamald N, Inokuma T, et al : In Vivo assessment of glucose metabolism in hepatocellular carcinoma with FD G-PET. J Nucl Med 36 : 1811-1817, 1995
7) 村野剛志 : 医療被曝におけるリスク・ベネフィット解析. 茨城県立医療大学修士論文, 茨城, 2004
8) 日本核医学会・臨床PET推進会議 : FDG-PETがん検診ガイドライン (2004). 核医学 41 : 1-21, 2004
10) 陣之内正史 : FDG-PETマニュアル検査と読影のコツ. (陣之内正史・編), インナービジョン, 東京, 61-63, 2003
14) 金子昌弘, 斉藤雄一, 宮坂善和・他 : 肺がん検診におけるFDG-PETの役割. 臨床放射線 49 : 873-879, 2004
15) Noguchi M, Morikawa A, Kawasaki M, et al : Small adenocarcinoma of the lung. Histologic characteristics and prognosis. Cancer 75 : 2844-2852, 1955
16) Pastrino U, Bellomi M, Landoni C, et al : Early lung-cancer detection with spiral CT and positron emission tomography in heavy smokers : 2 years results. Lancet 336 (23) : 593-597, 2003
P.97 掲載の参考文献
1) 日本気管支学会 : 気管支鏡臨床医のためのテクニックと画像診断. 医学書院, 東京, 1-21, 1998
4) 浅野文祐 : 極細径気管支鏡検査とVirtual Bronchoscopy. 気管支学 24 : 551-556, 2002
5) 坂英雄 : 末梢小型陰影の診断-極細径気管支鏡による生検診断-. 気管支学 26 : 487-489, 2004
6) 浅野文祐, 松野祥彦, 小牧千人・他 : 肺末梢小型病変に対する極細径気管支鏡を用いたCTガイド下の経気管支診断. 日呼吸会誌 40 : 11-16, 2002
8) 新島眞文, 江渡秀紀 : 末梢空洞性病変の診断に対する極細径気管支鏡の有用性. 気管支学 24 : 302-308, 2002
10) Schuurnans MM, Michaud GC, Diacon AH, et al : Use of an ultrathin bronchoscope in the assessment of central airway obstruction. Chest 124 : 735-739, 2003
12) 浅野文祐, 木村智樹, 進藤丈・他 : CTガイド下極細径気管支鏡検査の有用性-通常の経気管支生検で診断できなかった肺末梢病変に対する検討-. 気管支学 24 : 80-85, 2002
13) 浅野文祐, 足達広和, 佐藤寛之・他 : 極細径気管支鏡-肺末梢病変に対して-. 気管支学 26 : 694-696, 2004
17) 陳俊雄, 矢野孝子, 阿久沢浩司・他 : 径2cm以下の肺野孤立性腫瘤陰影に対する気管支鏡検査の診断的意義. 日胸疾会誌 34 : 266269, 1996
18) 遠藤正浩, 高田佳木, 大林加代子・他 : 2cm以下の末梢小型肺癌に対する経気管支診断と病理診断に関する考察. 肺癌 39 : 821-827, 1999
19) 田中繁, 梶川茂久, 森瓦希・他 : 細径気管支鏡は患者の負担を軽減できるか? -通常径気管支鏡との比較-. 気管支学 (in press)
21) 浅野文祐, 松野祥彦, 竹市直子・他 : Virtual Bronchoscopy-極細径気管支鏡ナビゲーションとして-. 気管支学 24 : 433-438, 2002
25) 浅野文祐 : 気管支内視鏡挿入支援システム. 肺癌 5 : 473, 2003
26) 浅野文祐, 松野祥彦, 鱸稔隆・他 : Virtual Bronchoscopyによるナビゲーションシステムを用いた呼吸器内視鏡診療. 気管支学 27 : 588-591, 2005
28) 浅野文祐, 松野祥彦, 鱸稔隆・他 : Auto-Guidance System for Insertion Bronchoscope+Thin GS-EBUSによる肺野末梢病変へのアプローチ. 気管支学 28 : 153, 2006
P.104 掲載の参考文献
2) 石坂彰敏, 斉藤達也. 非侵襲的な肺内生化学情報の収集 : 気道上皮被覆液採取のための気管支鏡的マイクロサンプリングプローベ. 医工学治療 12 : 711-713, 2000
10) 石坂彰敏, 渡辺真純. 気管支鏡下マイクロサンプリング法と肺癌診断. 綜合臨床 50 : 2242-2244. 2001
12) Cremendes MJ, Menendez R, Pastor A, et al : Diagnostic values of cytokeratin fragment 19 (CYFRA 21-1) bronchoalveolar lavage fluid in lung cancer. Respir, Med 92 : 766-771, 1998
13) Kohno N, Akiyama M, Kyoizumi S, et al : Detection of soluble tumor-associated antigens in sera and effusions using novel monoclonal antibodies, KL-3 and KL-6, against lung adenocarcinoma. Jpn J Clin Oncol 18 : 203-216, 1988
14) Wilkins MR, Pasquali C, Appel RD, Ou K, et al : From proteins to Proteomes : large scale protein identification by twodimensional electrophoresis and amino acid analysis. Bio technology 1 4 : 61-65, 1994
19) Hirano T, Kato H. Present status of clinical proteomic analysis for the early detection and determination of therapeutic strategy in lung cancer. Ann Thorac Cardiovasc Surg 12 : 4-9, 2006
21) Fung ET, Enderwick C. ProteinChip clinical proteomics : computational challenges and solutions. Biotechniques Suppl : 34-38, 40-41, 2002
P.111 掲載の参考文献
P.117 掲載の参考文献
1) Coultas DB, et al : Occupational lung cancer. Clinicsin chest medicine 13 : 341-354, 1992
2) World Cancer Research Fund, American Institute for Cancer Research et al : The American Institute for Cancer Research. Washington DC, 35-52, 1997
3) Spain DM : The association of terminal bronchiolar carcinoma with chronic interstitial inflammation and fibrosis of the lungs. Am Rev Tuberc 76 (4) : 559-566, 1957
4) Turner-Warwick M, Lebowitz M, Burrows B, et al : Cryptogenic fibrosing alveolitis and lung cancer. Thorax 35 (7) : 496-499, 1980
8) 大塚義紀, 浮田英明, 正木芳孝・他 : 特発性間質性肺炎 (IIP) からの肺癌発症-prospective study-. 日胸疾会誌 29 (5) : 560-565, 1991
9) 日本タバコ産業調査, 2002年
10) 嶋康晃 : 薬の知識 53 (10) : 254-263, 2002
12) U. S. Department of Health and Human Services. The Health Consequences of Smoking : Nicotine Addiction. A Report of the Surgeon General, 1988. U. S. Department of Health and Human Services, Public Health Services, Center for Disease Control, Center for Health Promotion and Education Office on Smoking and Health. DHHS Publication No. (CDC) 88-8406, Washington DC, 1988
18) Uematsu K, Yoshimura A, Gemma A, et al : Aberrations in the fragile histidine triad (FHIT) gene in idiopathic pulmonary fibrosis. Cancer Res 61 (23) : 8527-8533, 2001
19) Sozzi G, Sard L, De Gregorio L, et al : Association between cigarette smoking and FHIT gene alterations in lung cancer. Cancer Res 57 (11) : 2121-2123, 1997
20) 米山武志 : 肺がんのbed side epidemiology 6価クロム肺がん例の分析による発がん機序の考察. 日本胸部臨床 42 (12) : 997-1001, 1983
21) 肺がんを併発するじん肺の健康管理等に関する報告書. 肺がんを併発するじん肺の健康管理等に関する検討会, 2002
22) 岸本卓巳, 井内康輝 : 第II章 石綿関連疾患. 2肺がん (2) 診断. 産業保健ハンドブック石綿関連疾患-予防・診断・労災補償-, 財団法人産業医学振興財団. 52-60, 2004
P.123 掲載の参考文献
1) Schulz-Knappe P, Schrader M, Standker L, et al : Peptide bank generated by large-scale preparation of circulating human peptides. J Chromatogr A 776 (1) : 125-132, 1997
9) Adam BL, Qu Y, Davis JW, et al : Serum protein fingerprinting coupled with a pattern-matching algorithm distinguishes prostate cancer from benign prostate hyperplasia and healthy men. Cancer Res 62 (13) : 3609-3614, 2002
10) Qu Y, Adam BL, Yasui Y, et al : Boosted decision tree analysis of surface-enhanced laser desorption/ionization mass spectral serum profiles discriminates prostate cancer from noncancer patients. Clin Chem 48 (10) : 1835-1843, 2002
11) Banez LL, Prasanna P, Sun L, et al : Diagnostic potential of serum proteomic patterns in prostate cancer. J Urol 170 (2 Pt 1) : 442-446 2003
20) Taguchi F, Solomon B, Carbone DP, et al : Serum proteomic profiles for predicting response to gefitinib, a cross-laboratory technical validation study. AACR Meeting Abstracts Apr 2006 : 670, 2006
21) Solomon B, Gregorc V, Taguchi F, et al : Prediction of clinical outcome in non-small cell lung cancer (NSCLC) patients treated with gefitinib using Matrix-Assisted Laser Desorption/Ionization-Time of Flight Mass Spectrometry (MALDI-TOF MS) of serum. J Clin Oncol 2006 ASCO Annual Meeting Proceedings Part I. Vol 24, No 18S (June 20 Supplement), 7004, 2006
22) Perez EA, Suman VJ, Davidson NE, et al : HER2 testing by local, central, and reference laboratories in specimens from the North Central Cancer Treatment Group N9831 intergroup adjuvant trial. J Clin Oncol 24 (19) : 3032-3038, 2006

治療 ( 小細胞肺癌 )

P.134 掲載の参考文献
5) Nasser H, Paul A, Corey L, et al : Randomized phase III trial comparing irinotecan/cisplatin with etoposide/cisplatin in patients with previously untreated extensive-stage disease small-cell lung cancer. J Clin Oncol 24 : 2038-2043, 2006
6) Cisplatin Combined With Either Irinotecan or Etoposide in Treating Patients With Extensive-Stage Small Cell Lung Cancer SWOG-SO124 (USA)
7) Ando Y, Saka H, Ando M, et al : Polymorphism of UDP-Glucuronosy transferase gene and irinotecan toxicity : a pharmacogenetic analysis. Cancer Research 60 : 6921-6929, 2000
8) A Phase III Study Comparing IP With EP Following EP/TRT for LD-SCLC JCOG0202 (Japan)
10) Sekine I, Takeda K, Nishiwaki Y, et al : Randomized phase II trial of irrinotecan plus cisplatin (IP) versus irinotecan, cisplatin plus etoposide (IPE) every three weeks in patients with extensive disease small cell lung cancer. ASCO7087, 2006
13) 高齢者の進展型小細胞肺癌に対する塩酸アムルビシンの製造販売後臨床試験 (第III相), 大日本住友製薬株式会社
14) 塚田裕子, 横山晶, 瀬戸貴司・他 : 既治療小細胞肺癌に対する塩酸アムルビシンの第II相試験, 第44回日本癌治療学会総会, 2006
16) 尾下文浩, 斉藤春洋, 山田耕三・他 : 進展型小細胞肺癌に対する塩酸アムルビシンと塩酸イリノテカン併用療法の第I相試験, 第47回日本肺癌学会総会, 2006
17) Argiris A, Murren JR : Advances in chemotherapy for small cell lung cancer : single-agent activity of newer agents. Cancer J 7 (3) : 228-235, 2001
19) Seifar U, Fink T, Schade-Brittinge C, et al : Randomised phase II study comparing topotecan/carboplatin administration for 5 versus 3 days in the treatment of extensive-stage small-cell lung cancer. Ann Oncol Oct 27 : [Epub ahead of print], 2006
21) Yamamoto N, Turutani J, Yashimura N, et al : Phase II study of weekly paclitaxel for relapsed and refractory small cell lung cancer. An ticancer Res 26 (1B) : 777-781, 2006
22) Scocinski MA, Weissman C, Hart LL, et al : Randomized phase II trial of pemetrexed combined with either cisplatin or carboplatin in untreated extensive-stage small-cell lung cancer. J Cin Oncol 20, 24 (30) : 4840-4847, 2006
24) Carboplatin and Etoposide With or Without Thalidomide in Treating Patients With Limited-Stage or Extensive-Stage Small Cell Lung Cancer. LLCG-STUDY12 (UK)
25) Roger S, Christian M, Andrew T, et al : Small cell lung cancer : state of the art and future perspectives. Lung Cancer 45 : 105-117, 2004
P.141 掲載の参考文献
1) Zelen M : Keynote address on biostatistics and data retrieval. Cancer Chemother Rep (Part 3) 4 : 31-42, 1973
2) Kemofsky D, Abelmann W, Craver L, et al : The use of nitrogen mustards in the palliative treatment of carcinoma. Cancer 1 : 634, 1948
6) Roth BJ, Johnson DH, Einhom LH, et al : Randomized study of cyclophosphamide, doxorubicin, and vincristine versus etoposide and cisplatin versus altemation of these two regimens in extensive small-cell lung cancer : a phase III trial of the Southeastem Cancer study Group. J Clin Oncol 10 : 282-291, 1992
10) Chutte Jp, Chen T, Feigal E, et al : Twenty years of phase III trials for patients with extensive-stage small-cell lung cancer : perceptible progress. J Clin Oncol 17 : 1794-1801, 1999
12) Choi NC, Hemdon JE 2nd, Rosenman J, et al : Phase I study to determine the maximum-tolerated dose of radiation in standard daily and hyperfractionated-accelerated twice-daily radiation schedules with concurrent chemotherapy for limited-stage small-cell lung cancer. J Clin Oncol 16 (11) : 3528-3536, 1998
18) Kato T, Nokihara H, Ohe Y, et al : Phase II trial of amrubicin in patients with previously treated small cell lung cancer (SCLC). JCO, 2006 ASCO Annual Meeting Proceeding Part I. Vol 24, No. 185, 2006
20) Shields TVV, Higgins GA Jr, Humphrey EW, et al : Surgical resection in the management of small cell carcinoma of the lung. J Thorac Cardiovasc Surg 84 (4) : 481-488, 1982
24) Yamada K, Saijo N, Kojima A, et al : A Retrospective Analysis of Patients Receiving Surgery after Chemotherapy for Small Cell Lung Cancer. Jpn J of Clin Oncol 21 : 39-45, 1991
25) Auperin A, Arriagada R, Pignon JP, et al : Prophylactic cranial irradiation for patients with small cell lung cancer in complete remission. Prophylactic Cranial Irradiation Overview Collaborative Group. N Engl J Med 341 : 476-484, 1999
26) Pujol JL, Breton J, Gervais R, et al : A prospective randomized phase III, double-blind, placebo-controlled study of thalidomide in extensive-disease (ED) SCLC patients after response to chemotherapy (CT) : An intergroup study FNCLCC Cleo04-IFCT 00-01. JCO, 2006 ASCO proceeding 24, #7059
P.153 掲載の参考文献
2) Aisner J, Alberto P, Bitran J, et al : Role of chemotherapy in small cell lung cancer : A consensus report of the international association for the study of lung cancer workshop. Cancer Treat Rep 67 : 37-43, 1983
3) Einhom LH, Greco A, Wampler G, et al : Cytoxan, adriamycin, etoposide versus cytoxan, adriamycin, vincristine in the treatment of small cell lung cancer. Proc Am Soc Clin Oncol 6 : 168, 1987 (abstr)
6) Messeih AA, Schweitzer JM, Lipton A, et al : Addition of etoposide to cyclophosphamide, doxorubicine, and vincristine for remission induction and survival in patients with small cell lung cancer. Cancer Treat Rep 71 : 61-66, 1987
8) Schabel FM, Trader MW, Laster WK, et al : Cisdichlorodiamineplatinum (II) : Combination chemotherapy and crossresistance studies with tumors of mice. Cancer Treat Rep 63 : 1459-1473, 1979
10) Porter LL 3rd, Johnson DH, Hainsworth JD, et al : Cisplatin and etoposide combination chemotherapy for refractory small cell carcinoma of the lung. Cancer Treat Rep 69 : 479-481, 1985
13) Sierocki JS, Hilaris BS, Hopfan S, et al : Cisdichlorodiamineplatinum (II) and VP-16-213 : An active induction regimen for small cell carcinoma of the lung. Cancer Treat Rep 63 : 1593-1597, 1978
15) Roth BJ, Johnson DH, Einhom LH, et al : Randomized study of cyclophosphamide, doxorubicin, and vincristine versus etoposide and cisplatin versus alternation of these two regimens in extensive small-cell lung cancer : a phase III trial of the southeastern cancer study group. J Clin Oncol 10 : 282-291, 1992
16) Pujol J-L, Carestia, and Daures J-P : Is there a case for ciaplatin in the treatment of small-cell lung cancer? A metaanalysis of randomized trials of a cisplatin-containing regimen versus a regimen without this alkylating agent. Br J Cancer 83 : 8-15, 2000
17) Goldie JH, Coldman AJ and Gudauskas GA : Rationale for the use of altemating non-cross-resistant chemotherapy. Cancer Treat Rep 66 : 439-449, 1982
18) WK, Feld R, Murray N, et al : Superiority of alternating non-cross-resistant chemotherapy in extensive small cell lung cancer. A multicenter, randomized trial by the National Cancer Institute of Canada. Ann Intern Med 107 : 451-458, 1987
20) Coldman AJ, Goldie JH : Impact of dose-intense chemotherapy on the developement of permanent drug resistance. Semin Oncol 14 (Suppl 4) : 29-33, 1987
26) Murray N, Livingston RB, Shepherd FA et al : Randomized study of CODE versus alternating CAV/EP for extensive-stage small-cell lung cancer : An intergroup study of the National Cancer Institute of Canada Clinical Trials Group and the Southwest Oncology Group. J Clin Oncol 17 : 2300-2308, 1999
28) Bleehan NM, Fayers PM, Girling DJ, et al : Controlled trial of twelve versus six courses of chemotherapy in the treatment of small cell lung cancer : Report to the Medical Research Council by its Lung Callcer Working Party. Br J Cancer 59 : 584-590, 1989
29) Bleehan NM, Girling DJ, Machin D, et al : A randomised trial of three or six courses of etoposide cyclophosphamide methotrexate and vincristine or siX courses of etoposide and ifosfamide in small cell lung cancer (SCLC) : survival and prognostic factors. Br J Cancer 68 : 1150-1156, 1993
36) Niell HB, Hemdon JE, Miller AA, et al : Randomized phase III intergroup trial of etoposide and cisplatin with or without paclitaxel and granulocyte colony-stimulating factor in patients with extensive-stage small-cell lung cancer : Cancer and Leukemia Group B Trial 9732. J Clin Oncol 23 : 3752-3759, 2005
37) Reck M, von Pawel J, Macha HN, et al : Randomized phase III trial of paclitaxel, etoposide, and carboplatin versus carboplatin, etoposide, and vincristine in patients with small-cell lung cancer. J Natl Cancer Inst 95 : 1118-1127, 2003
39) Hanna N, Bunn Jr PA, Langer C, et al : Randomized phase III trial comparing irinotecan/cisplatin with etoposide/cisplatin in patients with previously untreated extensive-stage small-cell lung cancer. J Clin Oncol 24 : 2038-2043, 2006
42) 住友製薬 : カルセド製品情報概要. 2002年12月作成版
P.163 掲載の参考文献
3) Hryniuk W : Important Advance in Oncology 1988 (Eds・DeVit Jr VT, Hellen S, Rosenberg SA), J. B. Lippincott Company, Philadelphia, 121-141, 1988
4) Tjan-Heijnen VC, Wagener DJ, Postmus PE An analysis of chemotherapy dose and dose-intensity in small-cell lung cancer : lessons to be drawn. Ann Oncol 13 (10) : 1519-1530, 2002
6) Murray N, Livingston RB, Shepherd FA, et al : Randomized study of CODE versus alternating CAV/EP for extensive-stage small-cell lung cancer : an Intergroup Study of the National Cancer Institute of Canada Clinical Trials Group and the Southwest Oncology Group. J Clin Oncol 17 (8) : 2300-2308, 1999
9) Leyvraz S, Pampallona S, Martinelli G, et al : Randomized phase III study of high-dose sequential chemotherapy (CT) supported by peripheral blood progenitor cells (PBPC) for the treatment of small cell lung cancer (SCLC) : Results of the EBMT Random-ICE trial. ASCO Annual Meeting Proceedings Part 1. Vol 24, No. 18S (June 20 Supplement) 7064, 2006
10) 木浦勝行, 原田実根 : 末梢血幹細胞移植の実際 (原田実根, 薗田精昭, 高上洋一・編), 南江堂, 東京, 166-170, 2001
15) Brugger W, Fetscher S, Hasse J, et al : Multimodality treatment including early high-dose chemotherapy with peripheral blood stem cell transplantation in limited-disease small cell lung cancer. Semin Oncol 25 (Suppl 2) : 42, 1998
16) Bessho A, Ueoka H, Kiura K, et al : High-dose ifosfamide, carboplatin and etoposide with autologous peripheral blood progenitor cell transplantation for small-cell lung cancer. Anticancer Res 19 : 693, 1999
17) Kiura K, Ueoka H, Tabata M, et al : Phase II study of high-dose ifosfamide, carboplatin and etoposide with autologous peripheral blood stem cell transplantation for small-cell lung cancer Proc Am Soc Clin Oncol 22 (abstr 2540), 2003
27) Gilewski T, Norton L : Holland-Frei Cancer 7 medicine (Eds・Kufe DW, Bast Jr RC, Hait WN, Hong WK Pollock RE, Weichselbaum RR, Holland JF, Frei III E) BC Decker Inc, London, 570-589, 2006
28) Frei III E, Eder J : Holland-Frei Cancer 7 medicine (Eds・Kufe DW, Bast Jr RC, Hait WN, Hong WK, Pollock RE, Weichselbaum RR, Holland JF, Frei III E) BC Decker Inc, London, 590-599, 2006
P.171 掲載の参考文献
4) Johnson DH : Small cell lung cancer in the elderly patient. Semin Oncol 24 : 484-491, 1997
5) 西日本肺癌治療共同研究グループ : 高齢者小細胞肺癌はいかに治療すべきか? : 西日本肺癌治療共同研究グループにおけるアンケート調査. 癌と化学療法 26 : 797-804, 1999
19) Schmittel A, Fischer von Weikersthal L, Sebastian M, et al : A randomized phase II trial of irinotecan plus carboplatin versus etoposide plus carboplatin treatment in patients with extended disease small cell lung cancer. Ann Oncol 17 : 663-667, 2006
22) Radford JA, Ryder WD, Dodwell D, et al : Predicting septic complications of chemotherapy : An analysis of 382 patients treated for small cell lung cancer without dose reduction after major sepsis. Eur J Cancer 29A : 81-86, 1992
P.178 掲載の参考文献
1) Seifter EJ, Ihde DC : Therapy of small cell lung cancer : a perspective on two decades of clinical research. Semin Oncol 15 : 278-299, 1988
10) Porter LL, 3rd, Johnson DH, Hainsworth JD, et al : Cisplatin and etoposide combination chemotherapy for refractory small cell carcinoma of the lung. Cancer Treat Rep 69 : 479-481, 1985
11) Einhorn LH, Pennington K, McClean J : Phase II trial of daily oral VP-16 in refractory small cell lung cancer : a Hoosier Oncology Group Study. Semin Oncol 17 : 32-35, 1990
20) Kato T, Nokihara H, Ohe Y, et al : Phase II trial of amrubicin in patients with previously treated small cell lung cancer (SCLC). J Clin Oncol (Meeting Abstracts) 24 : 7061, 2006
26) Smyth JF, Smith IE, Sessa C, et al : Activity of docetaxel (Taxotere) in small cell lung cancer. The Early Clinical Trials Group of the EORTC. Eur J Cancer 30A : 1058-1060, 1994
29) Kim Y, Goto K, Nishiwaki Y, et al : Phase II study of weekly cisplatin, etoposide and irinotecan (PE/CPT) for refractory relapsed small cell lung cancer (SCLC). J Clin Oncol (Meeting Abstracts) 24 : 7088, 2006
31) Eckardt JR, von Pawel J, Hainsworth JD, et al : Single agent oral topotecan (PO) versus intravenous topotecan (IV) in patients (pts) with chemosensitive small cell lung cancer (SCLC). An intemational phase III study. Proc Am Soc Clin Oncol 22 : 619, 2003
32) O'Brien ME, Ciuleanu TE, Tsekov H, et al : Phase III trial comparing supportive care alone With supportive care with oral topotecan in patients with relapsed small-cell lung cancer. J Clin Oncol 24 : 5441-5447, 2006

治療 ( 非小細胞肺癌 )

P.184 掲載の参考文献
1) Japanese Association for Thoracic Surgery : Thoracic and cardiovascular surgery in Japan during 1999. Annual report by the Japanese Association for Thoracic Surgery. Jpn J Thorac Cardiovasc Surg 49 : 528-541, 2001
14) Swanson SJ, Herndon J, D'Amico A, et al : Results of CALGB 39802 : feasibility of video-assisted thoracic surgery (VATS) lobectomy for early stage lung cancer. J Clin Oncol 21 : A-1158, 2002
15) Raviaro G, Varoli F, Vergami C, et al : Long-term survival after videothoracoscopic lobectomy for stage I lung cancer. Chest 126 : 725-732, 2004
P.193 掲載の参考文献
7) International Commission on Radiation Units and Measurements (ICRU) : Report 62, ICRU Publications, 1999
8) Nagata Y, Takayama K, Matsuo Y, et al : Clinical outcomes of a Phase I/II study of 48Gy of stereotactic body radiation therapy in 4 fractions for primary lung cancer using a stereotactic body frame. Int J Radiat Oncol Biol Phys 63 : 5, 1427-1431, 2005
10) Onimanl R, Shirato H, Shimizu S, et al : Tolerance of organs at risk in small-volume, hypofractionated, image-guided radiotherapy for primary and metastatic lung cancers. Int J Radiat Oncol Biol Phys 56 : 126-136, 2003
11) Arimoto T, Usubuchi H, Matsuzawa T, et al : Small volume multiple non-coplanar arc radiotherapy for tumors of the lund, head & neck and the abdominopelvic region. CAR'98 Computer assisted radiology and surgery. edited by HU. Lemke, Elsevier, Tokyo, 1998
15) Timmemlan R, McGarry R, Yiannoutsos C, et al : Excesive toxicity when treating central tumors in a Phase II study of stereotactic body radiation therapy for medically inoperable early-stage lung cancer. JCO 24 : 4833-4839, 2006
17) Adler JR, et al : The Cyberknife : aframeless robotic system for radiosurgery. Stereotact Funct Neurosurg 69 : 124-128, 1997
18) Tamaki N, et al : C-arm multi-axis rotation stereotactic linac radiosurgery system. J of Radiosurgery 3 : 21-27, 2000
20) Kamino Y, Takayama K, Kokubo M, et al : Development of a four-dimensional Image-guided Radiotherapy system with a gimballed X-ray head. UROBP 66 : 271-278, 2006
P.200 掲載の参考文献
9) Matsuo K, Ito H, Yatabe Y, et al : Risk factors differ for non-small-cell lung cancers with and without EGFR mutation : assessment of smoking and sex by a case-control study in Japanese. Cancer Sci 2006
30) Miller VA, Zakowski M, Riely GJ, et al : EGFR mutation and copy number, EGFR protein expression and KRAS mutation as predictors of outcome with erlotinib in bronchioloalveolar cell carcinoma (BAC) : Results of a prospective phase II trial. J Clin Oncol (Meeting Abstracts.) 24 : 7003, 2006
P.210 掲載の参考文献
3) Herbst RS, et al : Selective oral epidermal growth factor receptor tyrosine kinase inhibitor ZD 1839 is generally welltolerated and has activity in non-small-cell lung cancer and other solid tumors : Results of a phase I trial. J Clin Oncol 20 : 3815-3825, 2002
21) Tokumo M, Toyooka S, Kiura K, et al : The relationship between epidemlal growth factor receptor mutations and clinicopathologic features in non-small cell lung cancers. Clin Cancer Res 11 : 1167-1173, 2005
27) Bailey R, et al : Tumor epidermal growth factor receptor (EGFR) expression levels does not predict for response in patients receiving gefitinib ("Iressa", ZD 1839) monotherapy for pretreated advanced non-small-cell lung cancer : IDEAL 1 and 2. Proc Am Assoc Cancer Res 44 : 1362 [abstr LB-170], 2003
34) Niho S, Kubota K, Goto K, et al : First-line single-agent treatment with gefitinib in patients with advanced non-smallcell lung cancer : A phase II study. J Clin Oncol 24 : 64-69, 2006
45) アストラゼネカ : イレッサ(R)錠250プロスペクティブ調査 (特別調査) に関する結果と考察 (2004年8月)
47) アストラゼネカ : ゲフィチニブ (イレッサ(R)錠250) の急性肺障害・間質性肺炎 (ILD) に関する専門家会議最終報告 (2003年3月26日)
P.220 掲載の参考文献
5) Bevacizumab : Anti-VEGF monoclonal antibody, avastin, rhumab-VEGF. Drugs R D 3 (1) : 28-30, 2002
8) Blumenschein G Jr, Sandler A, O'Rourke T, et al : Safety and pharmacokinetics (PK) of AMG 706, panitumumab, and carboplatin/paclitaxel (CP) for the treatment of patients (pts) with advanced non-small cell lung cancer (NSCLC) Proc-ASCO Vol 24, No 18S (June 20 Supplement), 2006
9) Fujisaka Y, Yamada Y, Yamamoto N, et al : Safety and Pharmacokinetics (PK) of AMG 706 in Japanese Patients with Advanced Solid Tumors. Proc-AACR-NCI-EORTC 55S, 2005
10) Wedge SR, Ogilvie DJ, Dukes M, et al : ZD6474 inhibits vascular endothelial growth factor signaling, angiogenesis, and tumor growth following oraladmin-istration. Cancer Res 62 : 4645-4655, 2002
13) Nakagawa K, Kiura K, Shinkai T, et al : A randomized double-blind phase II a dose-finding study of ZD6474 in Japanese patients with NSCLC Proc ASCO. Vol 24, No 18S (June 20 Supplement) : 7067, 2006
14) Heymach JV, Johnson BE, Prager D, et al : A phase II trial of ZD6474 plus docetaxel in patients with previously treated NSCLC Proc ASCO Vol 24, No 18S (June 20 Supplement) : 7016, 2006
15) Natale RB, Bodkin D, Govindan R, et al : ZD6474 versus gefitinib in patients with advanced NSCLC : Final results from a two-part, double-blind, randomized phase ll trial Proc ASCO Vol 24, No 18S (June 20 Supplement) : 7000, 2006
16) In vivo antitumor actiVity of SU11248, a novel tyrosine kinase inhibitor targeting vascular endothelial growth factor and platelet-derived growth factor receptors : determination of a pharmacokinetic/pharmacodynamic relationship. Mendel DB, Laird AD, Xin X, et al : Clin Cancer Res 15 ; 12 (20 Pt 1) : 6203-6204, 2006
P.226 掲載の参考文献
1) 日本肺癌学会/編 EBMの手法による肺癌診療ガイドライン2005年版 金原出版 東京, 2005
3) 日本呼吸器学会びまん性肺疾患診断・治療ガイドライン作成委員会編 特発性間質性肺炎診断と治療の手引き 南江堂, 東京 2004
6) Hertz MI, Boucck MM, Ceng MC, et al : Scientific registry of the International Society for Heart and Lung Transplantation : Introduction to the 2005 Annual Reports. J Heart Lung Transp 24 : 1182-1187, 2005
7) Turner-Warwick M, Lebowitz M, Burrows B, et al : Ciyptogenic fibrosing alveolitis and lung cancer Thorax 35 : 496-499, 1980
16) 岡本竜哉, 一安秀範, 一門和哉・他 : 特発性肺線維症の臨床的検討 急性増悪例の解析. 日本呼吸器学会雑誌 44 : 359-367, 2006
19) Yueksel M, Oezyurtkan MO, Bostanci K, et al : Acute exacerbation of interstitial fibrosis after pulmonary resection. Ann Thorac surg 82 : 336-338, 2006
24) 渡辺敦, 小柳哲也, 大澤久慶・他 : 間質性肺病変を伴う肺癌手術 とくに非合併例との比較. 胸部外科 58 : 9-14, 2005
25) 千田雅之, 高橋博人, 山中秀樹・他 : 限局性間質性肺炎からの肺癌手術後急性増悪例の検討. 胸部外科 58 : 22-25, 2005
27) 石井芳樹, 北村諭 : 特発性間質性肺炎急性悪化症例に対する好中球エラスターゼ阻害剤ONO5046の効果-後期第II相試験の成績-厚生省特定疾患呼吸器系疾患調査研究班びまん性肺疾患分科会平成8年度研究報告書. 240-244, 1997
28) 田中朋彦, 原田亮, 村木里誌・他 : 間質性肺炎合併肺癌例の術後急性増悪に対する有効な予防法. 胸部外科 58 : 41-45, 2005
29) 高岡一彦, 木村文平, 相河朋規・他 : 術前にびまん性肺野陰影を認めた原発性肺癌に対する手術. 胸部外科 58 : 31-35, 2005
30) 矢野篤次郎, 古賀聡 肺癌手術におけるステロイド予防投与-術後間質性肺炎予防に向けて. 胸部外科 58 : 37-40, 2005
31) 埴淵昌毅, 山口俊彦, 岡田達也・他 : 特発性間質性肺炎 (IIP) 合併肺癌に対する肺癌治療後IIP急性増悪症例の臨床的検討. 肺癌 41 : 281-286, 2001
32) 一瀬幸人, 坪井正博, 横田総一郎・他 : ゲフィチニブのコホート内ケースコントロールスタディ-ILDの相対リスクおよび危険因子の検討-. 肺癌 46 : 446, 2006
37) Peters-Golden M, Wise RA, Hochberg M, et al : Incidence of lung cancer in systemic sclerosis. J Rheumatol 12 : 1136-1139, 1985
P.234 掲載の参考文献
2) McDonald AC, Vasey PA, Adams L, et al : A phase I and pharmacokinetic study of LY231514, the multitargeted antifolate. Clin Cancer Res 4 : 605-610, 1998
5) Rusthoven JJ, Eisenhauer E, Butts C, et al : Multitargeted antifolate LY231514 as first-line chemotherapy for patients with advanced non-small-cell lung cancer : A phase II study. National Cancer Institute of Canada Clinical Trials Group. J Clin Oncol 17 : 1194-1199, 1999
19) Endo M, Yamamoto N, Sakai H, et al : Phase II study of 3 weekly S-1 plus cisplatin in patients with advanced nonsmall-cell lung cancer (NSCLC), S-1 cooperative study group. ESMO : 752P, 2006
21) Herskovic A, et al : Combined chemotherapy and radiotherapy compared with radiotherapy alone in patients with cancer of esophagus. N Eng J Med 326 : 1593-1598, 1992
23) Choy H, Safran H, Akerley W, et al : Phase II trial of weekly paclitaxel and concurrent radiation therapy for locally advanced non-small cell lung cancer. Clin Cancer Res 4 : 1931-1936, 1998
25) Browder T, Butterfield CE, Kraling BM, et al : Antiangiogenic scheduling of chemotherapy improves efficacy against experimental drug-resistant cancer. Cancer Res 60 : 1878-1886, 2000
27) Basaki Y, Aoyagi K, Chikahisa L, et al : UFT and its metabolites inhibit cancer-induced angiogenesis. Via a VEGF-related pathway. Oncology (Williston Park) 14 (10 Suppl 9) : 68-71, 2000
P.242 掲載の参考文献
1) Non-small Cell lung cancer Collaborative Group : chemotherapy in non-small cell lung cancer : a meta-analysis using updated data on individual patients from 52 randomised clinical trials. Br Med J 311 : 899-909, 1995
3) Fruse K, Fukuoka M, Kawahara M, et al : Phase III study of concurrent versus sequential thoracic radiotherapy in combination with mitomycin, vindesine, and cisplatin in unresectable stage III non-small cell lung cancer. J Clin Oncol 17 : 2692-2699, 1999
4) Curran WJ, Scott CB, Langer CL, et al : Long-term benefit is observed in a phase III comparison of sequential vs concurrent chemo-radiation for patients with unresected stage III NSCLC : RTOG 9410. Proc Am Soci J Clin Oncol 22 : 621, 2003
7) Gandara DR, Chansky K Albain KS, et al : Consolidation Docetaxel After Concurrent Chemoraditherapy in Stage IIIB Non-Small-Cell Lung Cancer : Phase n Southwest Oncology Group Study S9504. J Clin Oncol 21 : 2004-2010, 2003
10) Sause W, Kolerar P, Taylor S, et al : Final results of phase III trial in regionally advanced unresectable non-small cell lung cancer : Radiation Therapy Oncology Group, Eastem Cooperative Oncology Group, and Southwest Oncology Group.ohest 117 : 358-364, 2000
11) Schild SE, Stella PJ, Geyer SM, et al : Phase III trial comparing chemotherapy plus once-daily or twice-daily radiotherapy in Stage III non-small-cell lung cancer. Int J Radiat Oncol Biol Phys 54 : 370-378, 2000
13) Saunders M, Dische S, Barrett A, et al : Continuous hyperfractionated accelerated radiotherapy (CHART) versus convendonal radiotherapy in non-small-cell lung cancer : a randomised multicentre trial. CHART Steering Committee. Lancet 350 : 161-165, 1997
19) N Ready, p Janne, J Herndon, et al : Chemoradiotherapy (CRT) and gefitinib (G) in stage III non-small cell lung cancer (NSCLC) : A CALGB stratified phase II trial. Proc Am soc Clin Oncol 24 : 18s, 2006

診断・治療 ( 中皮腫, 胸膜・縦隔腫瘍 )

P.253 掲載の参考文献
1) Concensus report Asbestos, asbestosis, and cancer : the Helsinki criteria for diagnosis and attribution. Scand J Work Environ Health 23 : 311-316, 1997
2) 森永謙二 : 石綿関連疾患の疫学. Mebio 23 : 12-20, 2006
5) McDonald AD, McDonald JC : Epidemiology of malignant mesothehoma. In : Antman K Aisner J eds. Asbestos-related Malignancy Orland, Grune and Stratton, 31-55, 1987
6) Klelkowski D, Nelson G, Ree D : Risk of mesothelioma from exposure to crocidolite asbestos : a 1995 update of a South Africa mortality study. Occup En Viron Med 57 : 563-567, 2000
7) Beny G, Newhouse MI, Wagner JC : Mortality from all cancers of asbestos factory workers in east London 1933-1980. Occup Environ Med 57 : 782-785, 2000
8) Roushdy-Hammady I, Siegel J, Emri S, et al : Genetic-susceptibity factor and malignant mesothelioma in the Cappadocian region of Turkey. Lan cet 357 : 444-445, 2001
10) Pistolest M, Rusthoven J : Malignant pleural mesothelioma-update, current management, and newer therapeutic strategies-. Chest 126 : 1318-1329, 2004
12) Bianchi C, Brollo A, Ramani L, et al : Malignant mesothelioma in Europe. Int J Med Environ 28 : 103-107, 2000
14) 車谷典男, 熊谷信二 : わが国の胸膜中皮腫の記述疫学. THE LUNG perspectives 14 : 267-271, 2006
15) 岸本卓巳, 青江啓介, 玄馬顕一 : 平成17年度厚生労働科学特別研究 中皮腫と職業性アスベストばく露に関する研究報告書, 1-26, 2006
16) 岸本卓巳, 木村清延, 宇佐美郁治・他 : 我が国における中皮腫の臨床像-労働者健康福祉機構・労災病院グループ自験症例132例のまとめ, アスベスト曝露によって発生する肺がんと中皮腫に関する研究報告書, 6-19, 2006
17) 森永謙二 : 中皮腫トピックス 疫学. 日胸 65 : 587-593, 2006
P.262 掲載の参考文献
1) Rusch W : A proposed new international TNM staging system for malignant pleural mesothelioma. From the Intemational Mesothelioma Interest Group. Chest 108 : 1122-1128, 1995
3) 森永謙二編 : 職業性石綿ばく露と石綿関連疾患. 基礎知識と労災補償- (改訂新版). 三信図書, 東京, 2005
4) 独立行政法人労働者健康福祉機構編 : アスベスト関連疾患日常診療ガイド. アスベスト関連疾患を見逃さないために. 増補改訂版, 労働調査会, 東京, 2006
10) Hiraki A, Aoe K, Ueoka H : Asbestos exposure and serum osteopontin. N Engl J Med 354 : 304-305, 2006
13) Singhal S, Wiewrodt R, Malden LD, et al : Gene expression profiling of malignant mesothelioma. Clin Cancer Res 9 : 3080-3097, 2003
14) Gordon GJ, Jensen RV, Hsiao LL, et al : Translation of microarray data into clinically relevant cancer diagnostic tests using gene expression ratios in lung cancer and mesothelioma. Cancer Res 62 : 4963-4967, 2002
P.273 掲載の参考文献
1) 森永謙二, 井内康輝・他 : 石綿による健康被害に係る医学的判断に関する考え方報告書 (石綿による石綿被害に係る医学的判断に関する検討会による), 平成18年2月
2) 森永謙二, 井内康輝・他 : 悪性 (胸膜) 中皮腫に関するアンケート調査報告書 (平成15年度厚生労働省がん研究助成金による), 2004年2月11日
3) 岸本卓己, 井内康輝・他 : 中皮腫と職業性石綿ばく露に関する研究報告書 (平成17年度厚生労働科学特別研究による), 平成18年3月
4) Kushitani K Takeshima Y, Inai K, et al : Immunohistochemical panels for distinguishing between epithelioid malignanat mesothelioma and pulmonary adenocarcinoma. Pathol Int, 2007 (in press)
5) Kushitani K, Takeshima Y, Inai K, et al : Differential diagnosis between sarcomatoid mesothelioma and sarcoma, sarcomatoid carcinoma, (in submitted)
6) Churg A, Roggi V, Inai K, et al : Mesothelioma, in WHO CIassification of Tumours, Pathology & Genetics, Tumours of the lung, pleura, thymus and heart (Edit. By Travis WD et al), IARC Press, Lyon, 129-136, 2004
8) US-Canadian mesothelioma reference panel : The separation of benign and malignant mesothelial proliferations. Am J Surg Pathol 24 : 1183-1200, 2000
9) Inai K, et al : Pathology of malignant mesothelioma Ed, by Galateau-Salle F, Springer, Berlin, 2005
10) Churg A, Cagle PT, Roggli VL : AFIP Atlas of tumor pathology, Series 4, Tumors of the serosal membranes, ARP Press Silver Spring, Maryland, 83-101, 2006
P.279 掲載の参考文献
1) 立山義朗, 山本篤志, 栗原寛治, 他 : 最近の194剖検例における肺内のアスベストに関する所見. 広島医学 42 : 878-885, 1989
2) 神山宣彦 : 中皮腫における石綿曝露状況の分析法. 病理と臨床 22 : 667-674, 2004
3) 井内康輝 : アスベスト曝露と関連する胸膜・肺腫瘍. 検査と技術 34 : 704-707, 2006
4) 岸槌健太郎 : ヒト肺内に沈着するアスベスト繊維の分析-殊に肺癌, 悪性中皮腫発生との相関. 広大医学 43 : 279-295, 1995
9) 樋野興夫 : アスベスト救済. 読売新聞「論点」2005年10月27日付
10) 樋野興夫 : アスベスト・中皮腫より発がんを考える. 新農林技術新聞. 2005年12月15日付
11) 樋野興夫 : Asbestos-related mesothelioma ("Asbestoma") の血液診断. Human Scence, 2006 (印刷中)
12) 樋野興夫 : アスベスト・中皮腫の実態と診療・検査の実情. モダンメディア, 2006 (印刷中)
13) 樋野興夫 : 中皮腫トピックス 血液検査-早期診断を目指して-. 日本胸部臨床 2006 (印刷中)
14) 樋野興夫 : 胸膜悪性中皮腫血清マーカーについて. とくに, 中皮腫の血清マーカーについて. 呼吸器科, 2006 (印刷中)
15) 樋野興夫 : アスベストの検査法は? -とくに, 中皮腫の血清マーカーについて. 検査と技術, 2006 (印刷中)
16) Medical Ashai 2006年10月号 1921.
17) 樋野興夫 : アスベストと中皮腫 (亀井敏昭, 他監修), 第12章マーカーからみた中皮腫診断の考え方. 篠原出版新社, 東京, 2007 (印刷中)
18) 樋野興夫 : 中皮腫の血清診断マーカーの考え方. 最新医学 (印刷中)
P.289 掲載の参考文献